GCC · Announced 21 Oct 2026
Department of Health – Abu Dhabi / Cleveland Clinic Abu Dhabi → AstraZeneca
Deal between Department of Health – Abu Dhabi / Cleveland Clinic Abu Dhabi (United Arab Emirates) and AstraZeneca (United Kingdom), announced 21 Oct 2026.
Parties: Department of Health – Abu Dhabi / Cleveland Clinic Abu Dhabi (United Arab Emirates) → AstraZeneca (United Kingdom)
- Deal type
- Other
- Value
- See terms
- Territory
- United Arab Emirates
- Therapeutic area
- Cardiovascular
- Asset
- Feasibility exploration for up to 30 clinical trials in Abu Dhabi by 2030 — cardiovascular, kidney and metabolic focus; first six trials expected by end-2026; designed to address underrepresentation of Middle Eastern populations in drug research
- Announced
- 21 Oct 2026
Our analysis
Why this matters
AstraZeneca is now running research programs with both Gulf superpowers.
Two months after its KAIMRC pre-clinical deal in Saudi Arabia (Aug 2026, already in this tracker), AZ signed with DoH and Cleveland Clinic Abu Dhabi to explore up to 30 trials by 2030 in cardiovascular, kidney and metabolic disease — worth an estimated AED 180 million in research investment, with the first six trials starting by end-2026.
The full analysis is free to read with a work email on this page.